177Lu-PSMA-617

177Lu-PSMA-617 is an emerging radiopharmaceutical used in targeted radionuclide therapy for prostate cancer. This treatment involves the use of Lutetium-177 (177Lu) combined with PSMA-617, a small molecule that specifically targets prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer cells.

Virtual price, please inquire if needed.We can mass produce (kg level),process scaling up, pilot supply,raw material supply, and intermediate production. Our production technology is mature and more cost-effective. Feel free to inquire at any time.

msds of 177Lu-PSMA-617